BELGRADE, Mont., June 16, 2016 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rudy Mazzocchi to its Board of Directors. The Company also announced the resignation of Directors Jon Wickwire and David Goodman. The above changes will be effective as of July 2, 2016.
Paul Buckman has more than 30 years of experience as a business leader and executive in the medical device and medical technology industries, holding positions at SentreHEART, Pathway Medical Technologies, St. Jude Medical, Ev3, Scimed/Boston Scientific, and others. He has also served on the Board of Directors for businesses including SentreHEART,Sunshine Heart, Devax, Velocimed, EndiCor, Microvena, Micro Therapeutics, Ev3 and has served as the Chief Executive Officer for Conventus Orthopaedics since 2013.
Eric Timko has over 25 years in the medical industry, most recently serving as CEO of Blue Belt Technologies, a company that was acquired by Smith & Nephew earlier this year. Prior to joining Blue Belt, Mr. Timko was the President and CEO ofNeuroVasx, Inc., a Minneapolis-based company developing a unique therapeutic device to treat hemorrhagic stroke. Previously, he served as President of Carl Zeiss Surgical, Inc., and as Vice President of Siemens Medical Systems, Inc. Mr. Timko possesses a proven track record in building an effective and profitable sales and distribution organization and he brings vast experience in medical technologies at both the start-up and commercial stages.
Rudy Mazzocchi brings 27 years of senior management, intellectual property management and financing experience in the medical technology industry. He has founded and led five early-stage medical device companies from development through successful acquisitions in fields ranging from cardiology to neurosurgery. He has served as Chief Executive Officer of ELENZA, Inc., a company developing the world’s first electronic “AutoFocal” Intraocular Lens, since 2010, and concurrently serves as Executive Chairman of Establishment Labs, a developer and manufacturer of aesthetics and plastic surgery implantable devices. Mr. Mazzocchi was formerly President and Chief Executive Officer of NovaVision, Inc., and served as Managing Director of Accuitive Medical Ventures, an early stage venture capital fund. Mr. Mazzocchi also served as President and Chief Executive Officer of Image-Guided NEUROLOGICS, seeing it through an acquisition byMedtronic, Inc. in 2005. Prior to that, he founded Microvena, eventually known as the public-company, Ev3, which was acquired by Covidien in 2010. Most recently, Mr. Mazzocchi served as Executive Chairman of Vascular Pathways, Inc. and led its acquisition by C.R. Bard in July 2015.
“I am excited to announce the addition of these highly qualified individuals to our board of directors, with each bringing extensive medical device management experience to the organization,” said Dan Goldberger, CEO of Xtant Medical. “I would also like to express my sincere gratitude to Mr. Wickwire and Dr. Goodman for their service to the Board and Xtant Medical; their strategic advisement helped guide the Company through significant growth and change.”
The Company also announced that Dr. David Kirschman has resigned from his position as Executive Vice President and Chief Scientific Officer of Xtant Medical, in order to concentrate on his continuing role as an Xtant board member.
“Dan Goldberger and the Xtant management team have earned my confidence and I feel that under his continued leadership, combined with that of our senior management team, Xtant will continue to build upon its success,” stated Dr. Kirschman, Director.
As the founder of X-spine Systems, Inc., and major shareholder of Xtant Medical, Dr. Kirschman remains highly committed to the company, its employees and its customers. Through his role as a director, he will continue to positively influence the Company at the highest level of strategy and governance. This transition will also allow Dr. Kirschman to pursue outside personal and professional interests. This change will also take effect on July 2, 2016.